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Abstract Epidemiologic data in adult men exhibit a strong
relationship between erectile dysfunction (ED) and lower
urinary tract symptoms suggestive of benign prostatic hy-
perplasia (LUTS/BPH), indicating that men affected by ED
should also be investigated for LUTS/BPH and those
presenting with storage or voiding LUTS should be investi-
gated for co-morbid ED. Common pathophysiolgical mech-
anisms underlying both LUTS/BPH and ED, including
alteration of NO/cGMP or RhoA/Rho-kinase signaling
and/or vascular or neurogenic dysfunction, are potential
targets for proposed phosphodiesterase type 5 inhibitors
(PDE5-Is). Several randomized controlled trials and only
a few reviews including all commercially available
PDE5-Is demonstrated the safety and efficacy of these
drugs in the improvement of erectile function and urinary
symptoms, in patients affected either by ED, LUTS, or
both conditions.
Keywords Benign prostatic hyperplasia . Lower urinary
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Introduction
Erectile dysfunction (ED) and lower urinary tract symptoms
suggestive of benign prostatic hyperplasia (LUTS/BPH) are
common conditions in middle-aged or older men. Several
reports indicated that patients with ED have a higher preva-
lence of LUTS strictly related to the urinary symptoms sever-
ity [1••]. Although the underlying mechanisms for the
relationship between ED and LUTS/BPH men are not fully
understood, it has been hypothesized that impaired NO/cGMP
signaling could be the relevant underlying determinant for the
pathophysiology of both ED and LUTS/BPH, suggesting that
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phosphodiesterase type 5 (PDE5) inhibitors (Is) are beneficial
for the treatment of both conditions [2, 3••, 4–6].
PDE5 gene and protein expression has been described
across the whole human lower urogenital tract, with differ-
ent patterns of appearance [5, 7•]. The mechanism of action
of PDE5-Is on LUTS/BPH includes several potential sites of
actions such as the prostate and/or bladder [8, 9]. The
remarkable improvement of urodynamic parameters during
treatment with PDE5-Is, both in men with spinal cord injury
[10] or during continence recovery after radical prostatecto-
my for prostate cancer [11], underline the importance of the
bladder as a target of PDE5-Is in LUTS. In addition, pelvic
ischemia due to the pelvic artery insufficiency, caused by
metabolic syndrome (MetS), can induce functional and
morphological changes of the bladder and prostate, that
can be restored by the use of PDE5-Is [12, 13].
At the present time, several clinical trials on the use of
PDE5-Is - either alone or in combination with other drugs
(such as α-blockers) in men with LUTS/BPH and co-
morbid ED - have been reported in literature [3••]. All
commercially available PDE5-Is have been tested in men
with LUTS/BPH, with or without ED, by analyzing both
urinary and sexual symptoms.
The aim of the present review is to summarize the current
literature concerning the use of PDE5-Is for the treatment of
LUTS/BPH and concomitant ED by analyzing epidemiolog-
ical data, common pathophysiological pathways and effica-
cy as well as safety outcomes of clinical trials on PDE5-Is
for ED and LUTS/BPH.
Epidemiology Data Concerning Comorbidity of ED
and LUTS/BPH
Several national or cross-national studies, based on an un-
selected population of LUTS/BPH or ED patients, demon-
strated a tight correlation between LUTS/BPH and ED. We
analyzed the results of the most important single center and
cross sectional trials.
Single Center Trials
LUTS and ED are highly prevalent in men with BPH (see
Table 1) [14–26]. Despite well-known risk factors of ED, such
as age, diabetes, drugs, coronary artery disease or behavior,
several studies have shown that the increasing prevalence of
ED is related to the increasing severity of LUTS.
The Cologne Male Survey, a community-based study in
4477 men aged 30–80 years, demonstrated that the overall
prevalence of LUTS was significantly higher in men with
ED than in those without ED (72 % vs. 38 %) [15]. Simi-
larly, in another study from UK enrolling 11,327 men, with
median age of 60 years at the diagnosis of ED, with any
recorded LUTS/ED, the odds ratios (OR) for ED in men
with LUTS compared to those without LUTS were: storage
LUTS 3.0, voiding LUTS 2.6 and both storage and voiding
LUTS 4.0. Moreover, LUTS diagnosis preceded ED in
63.1 % of patients by a mean of 4.8 years [17].
More recently, several authors have looked for the corre-
lation between LUTS and ED in a population screened for
prostate cancer. In particular, in a Brazilian study on 1008
consecutive patients enrolled in a prostate cancer screening
program, with a mean age of 61.2 years (range 45–87), only
5.4 % of the patients without ED had severe LUTS, com-
pared to 27.1 % of patients with severe ED (P<0.001) [19].
Multicenter Trials
Several cross-sectional multicenter trials investigating the
epidemiological association between LUTS and ED have
been published in the last 10 years (see Table 1).
The National Health and Social Life Survey, a
community-based involving 1410 men aged 18–59 years
demographically representative of US adults, demonstrated
that LUTS are significant risk factors for ED, with an OR of
3.13 [14].
Later on in 2003, three different cross-national studies
were published. In a study carried out in Brazil, Italy, Japan
and Malaysia on 2412 men aged 40–70 years, Nicolosi et al.
[20] evaluated the prevalence of ED and associated factors
among men without concomitant diseases. Among 1335
healthy men, the prevalence of ED was 16.1 %. In this
population, age, cigarettes smoking and LUTS were all
associated with an increased risk of ED. The UrEpik study
group, including 4800 men aged 40–79 years, from
Auxerre, Birmingham, Boxmeer and Seoul [21], demon-
strated that both the presence of BPH and LUTS severity
were associated with an increased risk of ED, similar to that
observed in subjects with diabetes and hypertension. In
addition, the results of the Multinational Survey of the
Aging Male (MSAM-7), a survey in 12,815 men aged 50–
80 years conducted in the United States and six European
countries to investigate the relationship between LUTS and
ED in older men, clearly demonstrated that erection prob-
lems significantly increased with both age and LUTS sever-
ity [22]. In this study, ED was reported by 30 %, 51 %, and
76 % of study participants aged 50–59 years, 60–69 years,
and 70–80 years, respectively (p<0.001) and in 43 %, 66 %,
and 83 % of men with mild, moderate, and severe LUTS,
respectively (p<0.001).
The Tampere Aging Male Urological Study, a prospec-
tive population-based postal survey in Finland in 1683 men
aged 50–70 years followed for 5 years, reported an associ-
ation between the severity of ED at baseline and the inci-
dence of LUTS or bother during follow-up [16]. In line with
these data, the European Male Aging Study, a multicenter
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population-based survey, performed on more than 3400
subjects across eight European centers, found that LUTS
severity was significantly associated with ED and lower
quality of life independent of other associated morbidities
[27]. In 2008, McVary et al. published the retrospective US
claims data analysis of 81,659 men with a mean age of
57 years. The authors analyzed men with a new diagnosis
or medication for ED, and showed a baseline LUTS/BPH
prevalence of 1.5 %, and demonstrated a total prevalence of
7.6 % after two years follow-up [18].
Evidence linking disorders of the prostate and bladder
with LUTS and ED is irrefutable, but the contribution of
metabolic, cardiovascular, and endocrine factors cannot be
discounted. In 2010, the Men in Australia Telephone Survey
(MATeS) study, including 5990 men aged ≥40 years, eval-
uated lifestyle and biomedical associations as possible
causes of ED, prostate disease, LUTS and perceived symp-
toms of androgen deficiency in a representative population
of middle-aged and older men. They demonstrated that
diabetes mellitus and cardiovascular diseases were both
Table 1 Association between lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) and erectile dysfunction (ED)
in single- and multicenter trials
Authors/
Country





National Health and Social
Life Survey
1410 men (aged 18–59) - 10 %
Self-report of LUTS, 1 question on ED
Braun et al. [15]
(Germany)
Cologne Male Survey 4477 men (aged 30–80) 44 % 19 %
IPSS, 18 questions KEED




1126 men (aged 50–70) - 70 %




database in 333 general
practices in UK
11,327 men with LUTS and ED,
aged >18 years questionnaire
assessing voiding and storage LUTS




Retrospective US claims data
analysis (1999–2004)
81,659 men with ED (mean age 57 years) - at baseline: 1.5 %
after 2 years:7.6 %IPSS
Antunes et al.
[19] (Brazil)
Prostate cancer screening program
in San Paulo (Brazil)
1008 men screened for PCa ( mean
age 61 years)
81.4 % mild 52 %,
moderate30%
severe 17 %.IPSS, IIEF
Multicenter trials
Nicolosi et al. [20]
(international)
ED Epidemiology Cross National
Study (Brazil, Italy, Japan, Malaysia)
2412 men (aged 40–70) - 16 % in healthy
men (32 % in
other men)
IPSS, 1 question on ED
Boyle et al. [21]
(international)
UrEpik Study Group. (UK,
Netherlands, France, Korea)
4800 men (aged 40–79) - 21 %
IPSS, O'Leary's Sexual Function Inventory
Rosen et al. [22]
(international)
Multinational survey of the aging
male (MSAM-7) USA/Europe
12,815 men (aged 50–80) 90 % 49 %
IPSS, DAN-PSSsex, IIEF
Holden et al. [23]
(Australia)
Men in Australia Telephone Survey
(MATeS)
5990 men (aged ≥40) 16 % 21 %
IPSS, 1 question on ED ED/LUTS + prostate disease +
androgen deficiency: 34 %
Wein et al. [24]
(international)
Epidemiology of LUTS (EpiLUTS)
study USA, UK, Sweden
11,834 men (mean age 56.1) - 26 %
SF-12, IPSS, IIEF, Male Sexual Health
Questionnaire,
Frankel et al. [25]
(international)
12 countries: Community population
and Urology clinic
423 (aged 40) community - In Clinic men: 60 %
1271 (aged>55) with LUTS/BPH
ICSmale and ICSsex questionnaires





994 men (aged 40–88 years) with BPH 90 % 82 %
IPSS, DAN-PSS, IIEF-5
DAN-PSS = Danish Prostate Symptom Score; IPSS = International Prostate Symptom Score; ED = erectile dysfunction; LUTS = lower urinary tract
symptoms; BPH = benign prostatic hyperplasia; SF = sexual function; QoL = quality of life; ICS = International Continence Society; KEED =
Cologne Erectile Inventory; IIEF = International Index of Erectile Function
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associated with ED, and hypertension was strongly associ-
ated with LUTS and perceived symptoms of androgen defi-
ciency, while cigarettes smoking and depressive symptoms
were the only variables independently associated with pros-
tate diseases [23]. This was a first clue of the potential
relationship between metabolic syndrome (including BMI
and waist circumference), LUTS and ED.
Pathophysiology and Mechanisms of Action
of PDE5-Is on both ED and LUTS
There is an increasing body of evidence that all theories
currently proposed for a common causality for both ED and
LUTS are interconnected and that treatment options may
overlap allowing prevention and/or treatment of both con-
ditions simultaneously. These pathophysiolgoical pathways,
which are also possible targets for the treatment of both ED
and LUTS/BPH with PDE5-Is, are: a) modification of the
nitric oxide/cyclic guanosine monophosphate (NO/cGMP)
pathway; b) improvement of the RhoA/Rho-kinase (ROCK)
pathway; c) hyperactivity of autonomic nervous system; d)
atherosclerosis of pelvic vessels (see Fig. 1).
The NO/cGMP pathway in the regulation of erection has
been well clarified [28]; currently, there is a body of evidence
for a role of NO in the regulation of smooth muscle tone of
bladder, prostate and urethra [29]. In particular, calcium-
dependent NOS, including endothelial (eNOS) and neuronal
(nNOS) have been described in several lower urinary tract
(LUT) tissues. The nNOS isoform was identified in nerve
terminals of the prostate, specifically in the peripheral and
transitional zones [30]. NOS activity has also been described
in the urothelium, smooth muscles, blood vessels, and nerves
of the bladder [31]. A potential role for the NO pathway in
LUTS/BPH is suggested by the proof of antiproliferative and
pro-apoptotic effects of NO donors on culture of bladder,
prostate and urethra smooth muscle cells [32].
An overactivity of the contractile RhoA/ROCK pathway has
further been indicated as a common pathological mechanism
underlying both ED and LUTS. Pathological conditions that
alter relaxant/contractile mechanisms balance, such as those
associated with reduced function of NO production and/or
overactivity of RhoA/ROCK contractile signaling (i.e., aging,
hypertension, smoking, diabetes and MetS), cause impaired
smooth muscle relaxation in both penile and LUT tissue func-
tion, leading to ED and uncontrolled detrusor contractility [8,
33, 34]. Up-regulated RhoA/ROCK signaling has been dem-
onstrated in corpora cavernosa [35] and bladder [36] of spon-
taneously hypertensive rats (SHR), a rat strain predisposed to
erectile dysfunction, BPH and overactive bladder. Similarly,
hyperactivation of RhoA/ROCK signaling has been demon-
strated in penis and bladder tissue in an animal model of MetS
[37, 38]. The inhibition of ROCK can limit bladder hyperac-
tivity, reduce contractions in bladder strips from SHR and
improves erection [35]. Interestingly, PDE5 inhibition with
vardenafil reversed RhoA/ROCK hyperactivation in SHR;
thus, preventing deterioration of urodynamic parameters [9].
Another important mechanism linking ED to LUTS is the
autonomic hyperactivity with an increased sympathetic tone
[39]. Various subtypes of α1-adrenergic receptors have been
identified in the bladder, prostate and penile tissue, mediating
the tone of smooth muscle vasculature [40, 41]. In particular,
α1A- and α1D- receptors have been recognized as the predom-
inant α-adrenoceptor subtypes in the penis. α1A-adrenoceptors
identified in bladder neck and prostate are involved in
voiding symptoms while α1D-adrenoceptors, concentrated in
hypertrophied detrusor muscle, are involved in storage symp-
toms [42]. Correlation between autonomic hyperactivity and
LUTS/ED has been further suggested by preclinical studies
using SHRs, which were shown to develop increased autonom-
ic activity, BPH, LUTS, and ED [43, 44].
Atherosclerosis of the penis and lower urinary tract is
indicated as a further potential mechanism which ties all the
previously described pathways, since pelvic atherosclerosis
reduces NO signaling, up-regulates RhoA-ROCK, and is a
component of the metabolic syndrome/autonomic hyperac-
tivity. Traditional risks factors for ED and atherosclerosis,
such as diabetes mellitus and hypertension, can also affect
LUTS/BPH [45, 46]. Several pre-clinical and clinical trials
have demonstrated that bladder ischemia/hypoxia can be
strongly associated with alteration of erectile and LUT tis-
sues [47, 48]. A positive immunostaining for the hypoxia-
inducible factor 1α (HIF-1α), a protein not present in nor-
mal cells but induced under hypoxic conditions, has been
Fig. 1 Schematic presentation of common pathophysiological mecha-
nisms linking erectile dysfunction (ED) to lower urinary tract symptoms
suggestive of benign prostatic hyperplasia (LUTS/BPH). All components
are potential targets for phosphodiesterase type 5 inhibitors (PDE5-Is). NO
nitric oxide; cGMP cyclic guanosine monophosphate; ROCK Rho-kinase;
BPH benign prostatic hyperplasia; LUTS lower urinary tract symptoms;ED
erectile dysfunction; PDE5-Is phosphodiesterase type 5 inhibitors
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identified in prostatic tissue from patients with BPH, while no
HIF-1α immunostaining was detected in tissue from healthy
controls [49]. Finasteride, a 5α-reductase inhibitor, reduces
prostate size through reducing HIF-1α and other hypoxia-
related growth factors, which can contribute to the growth of
prostate [50]. In animal models of chronic ischemia of the
lower urinary tract [12] and penis [51–54], administration of
PDE5-Is restored normal oxygenation, thereby preventing
tissue fibrosis and functional modifications.
In conclusion, PDE5-Is may exert beneficial effects on
smooth muscle relaxation, smooth muscle and endothelial
cell proliferation, nerve activity, and tissue perfusion at both
the lower urinary tract and penile level, thus affecting major
mechanisms contributing to ED and LUTS, including re-
duced NO/cGMP/PKG signaling, increased RhoA kinase
pathway activity, autonomic overactivity, and tissue ische-
mia [55, 56, 57•, 58–64]. Together, these effects on the
mechanisms overlapping ED and LUTS pathophysiology
may explain the positive effects of PDE5 inhibition on both
conditions reported to date.
Evidence Syntesis on PDE5-Is and LUTS/BPH
In 2002, Sairam et al. first suggested that PDE-Is can ame-
liorate LUTS in men attending the andrology outpatient
clinic for ED [65]. In 2006, Mulhall confirmed this obser-
vation in a population of men with co-morbid ED and mild
to moderate LUTS [66]. During the following years, in a
study of men with LUTS/BPH with or without ED, McVary
et al. conclusively established the emerging role of PDE5-Is
as an effective and well tolerated treatment for LUTS [67].
After these studies, several clinical trials have investigated
the use of PDE5-Is in LUTS/BPH men. Until November
2012, only three systematic reviews [3••, 68, 69] on the use
of PDE5-Is alone or in combination with α-blockers in
LUTS/BPH men have been published, of which only one
[3••] included a meta-analysis.
Sildenafil
McVary et al. [70] evaluated for the very first time in literature
the role of sildenafil for LUTS/BPH in a double-blind, place-
bo controlled study in men aged 45 years or older who
scored ≤25 on the IIEF-erectile function domain and ≥12 on
the IPSS questionnaire. The authors reported a significant
improvement in IEEF with sildenafil compared to placebo
(9.17 vs. 1.86, p<0.0001). Moreover, they described signifi-
cant improvements of both IPSS and BPH Impact Index (BII)
with sildenafil compared to placebo (IPSS −6.32 vs. –1.93,
p<0.0001; BII −2.0 vs. –0.9, p<0.0001, respectively). No
differences of maximum urinary flow rate (Qmax) were ob-
served between the groups (p=0.08).
Kaplan et al. [71] evaluated 62 men aged 50–76 years with
previously untreated ED and LUTS/BPH randomized to
alfuzosin (n=20), sildenafil (n=21), or the combination of both
(n=21) for 12 weeks. Sexual function (IIEF-score) was not
statistically improved with alfuzosin alone (+16.7 %, p=0.11),
whereas it was improved with either sildenafil alone (+49.7 %,
p=0.01) and the combination of alfuzosin and sildenafil (+58.
6 %, p=0.002). LUTS (IPSS) were significantly ameliorated
with alfuzosin (−15.6%, p=0.01) and sildenafil alone (−16.9%,
p=0.03) and even more with combination therapy (−24.1 %,
p=0.002). There was a significant improvement in Qmax with
alfuzosin alone (11.7 %, p=0.03) or in combination with silden-
afil (21.1 %, p=0.02) but not with sildenafil monotherapy.
Tuncel et al. [72] screened 60 men with LUTS/BPH who
were randomized to receive sildenafil only (n=20),
tamsulosin only (n=20) or the combination of sildenafil
and tamsulosin (n=20) for 8 weeks. Sildenafil monotherapy
was compared with combination treatment regarding erec-
tile function and, in particular, the improvements of ques-
tions 3 (frequency of sexual intercourse) and 4 (maintenance
of erections) of the IIEF-questionnaire; improvements were
83.3 % vs. 75.0 % (p=0.438) and 73.3 % vs. 89.1 %
(p=0.083), respectively. The improvements of IPSS after
8 weeks were 40.1 % for combination therapy vs. 36.2 %
for tamsulosin monotherapy (p=0.206) and 28.1 % for
sildenafil monotherapy (p<0.001). The mean improvement
of Qmax for sildenafil or tamsulosin monotherapy was
26.9 % and 26.2 % (p=0.870), respectively while improve-
ment for combination therapy was 42.0 % (p<0.001).
Sildenafil was well tolerated when used for LUTS/BPH,
with an overall incidence of adverse events (AEs) of 31 %
(50/160) of all patients treated with sildenafil in
monotherapy vs. 7.7 % (12/155) of patients treated with
placebo and in 15 % (3/19) of all patients treated with
sildenafil alone vs. 11 % (2/18) of men treated with combi-
nation therapy [3••].
Tadalafil
Tadalafil has been more extensively and systematically inves-
tigated for the use in LUTS/BPH than any other PDE5-I. All
tadalafil trials were randomized, double-blind, placebo-
controlled trials in men with LUTS/BPH >6 months, aged
≥45 years, IPSS ≥13 at start of placebo lead-in period, and
Qmax between 4 and 15 ml/s. All trial participants had a 4-week
washout and a 4-week placebo lead-in phase. Trial duration
was usually 12 weeks and only the open-label trial lasted
52 weeks. Common efficacy parameters in all trials were IPSS
(including IPSS storage and voiding sub-scores), BII, and IIEF
in sexually active men with ED, with special focus on the
erectile function (EF) domain of the questionnaire. Safety
parameters included treatment-emergent adverse events
(TEAEs), post-void residual urine, and Qmax.
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In 2007, McVary et al. [67] investigated 281 men randomly
allocated to 5 mg tadalafil once daily for 6 weeks, followed by
dose escalation to 20 mg once daily for another 6 weeks, or
placebo for 12 weeks. The improvement of sexual function
was significant for tadalafil vs. placebo (IIEF: +8.4 vs. +1.6,
p<0.001). Moreover, LUTS improvement was greater with
tadalafil vs. placebo at week 6 (mean improvement of IPSS:
49.3 % vs. 36.4 %, p=0.03) and week 12 (60.9 % vs. 42.7 %,
p<0.01), while Qmax was not significantly changed in both
treatment groups throughout the study.
Roehrborn et al. [73] evaluated 1058men with LUTS/BPH
with or without ED. Patients were randomly allocated to
receive tadalafil 2.5 mg, 5 mg, 10 mg, 20 mg or placebo once
daily for 12 weeks. IIEF-EF significantly improved after
12 weeks of treatment: +5.59 for tadalafil 2.5 mg, +6.97 for
tadalafil 5 mg, +7.98 for tadalafil 10 mg, and +8.34 for
tadalafil 20 mg; the differences compared to placebo (+2.2)
were significant for all tadalafil doses (p<0.001). Regarding
LUTS, mean changes of IPSS from baseline to study end were
also significantly different for all tadalafil doses: -3.9 for
tadalafil 2.5 mg (p=0.015), -4.9 for tadalafil 5 mg
(p<0.001), -5.2 for tadalafil 10 mg (p<0.001), and −5.2 for
tadalafil 20 mg (p<0.001) as compared to placebo (−2.3)
while Qmax, although increased with increasing tadalafil dose,
was insignificant for all treatment groups.
Porst et al. [74] investigated 581 LUTS/BPH men with
ED treated with placebo or tadalafil 2.5 mg, 5 mg, 10 mg, or
20 mg once daily for 12 weeks. The overall improvement of
sexual function with tadalafil was significant for all tadalafil
treated patients. With once-daily tadalafil, normal erectile
function (IIEF-EF domain score >26) was attained at end
point in 21.2 % (24/113 men) with 2.5 mg, 34.2 % (40/117
men) with 5 mg, 42.5 % (51/120 men) with 10 mg and
40.0 % (46/115 men) with 20 mg of tadalafil vs. 14 % with
placebo. Moreover, tadalafil significantly ameliorated
LUTS/BPH compared to placebo treated men: mean
changes in IPSS were −2.1 with placebo, -3.6 with tadalafil
2.5 mg (p=0.043), -4.2 with tadalafil 5 mg (p=0.004), -4.7
with tadalafil 10 mg (p<0.001), and −4.7 with tadalafil
20 mg (p<0.001). In contrast, Qmax was not significantly
different for any tadalafil group vs. placebo.
In a second study of Porst et al. [75], the authors ran-
domized 325 men who were treated with either tadalafil
5 mg (n=161) or placebo (n=164). IIEF-EF score in sexu-
ally active men with ED improved after 12 weeks of
tadalafil vs. placebo (6.7 vs. 2.0; p<0.001). Tadalafil also
significantly improved IPSS from baseline to endpoint as
compared to placebo (−5.6 vs. -3.6; p=0.004), while
uroflowmetry parameters did not significantly change at
study end.
Recently, Oelke et al. [76] designed a randomized,
double-blind, placebo-controlled, parallel-group study in
men with LUTS/BPH. In total, 511 patients were
randomized to placebo (n=172), tadalafil 5 mg (n=171),
or tamsulosin 0.4 mg (n=168) once daily and were treated
for 12 weeks. However, the study was not powered to
directly compare both active compounds. Compared to pla-
cebo, sexual function significantly improved with tadalafil
but not with tamsulosin in sexually active men with ED
(IIEF-EF score +4.0, p<0.001 and −0.4, p=0.699, respec-
tively). Moreover, LUTS/BPH significantly decreased with
tadalafil and tamsulosin as compared to placebo as early as
one week after start of treatment. Significant LUTS/BPH
improvement was documented throughout the study period;
at study end, IPSS decreased by −2.1 with tadalafil 5 mg
(p=0.001) and −1.5 with tamsulosin 0.4 mg (p=0.023)
relative to placebo. Finally, Oelke et al. first reported about
a significant increase of Qmax with both tadalafil and
tamsulosin, as compared to placebo: Qmax +2.4 ml/s for
tadalafil (p = 0.009) and +2.2 ml/s for tamsulosin
(p=0.014). This data was corroborated by similar improve-
ments of average urinary flow rate with both tadalafil
(+1.6 ml/s, p=0.002) and tamsulosin (+1.3 ml/s, p=0.023).
Donatucci et al. conducted a 1-year, open-label extension
study reporting the long-term safety and maintenance of
efficacy for the once daily use of tadalafil 5 mg in men
with LUTS/BPH. The study population consisted of 427
men who completed the 12-week, double-blind, placebo-
controlled period [73]. In total, 299 patients (69.9 %)
completed the 1-year, open-label extension period. TEAEs
were reported by 57.6 % of patients, with most TEAEs
being mild (44 %) or moderate (45 %) in severity; the
most common TEAEs (≥2 %) were dyspepsia, gastro-
oesophageal reflux disease, back pain, headache, sinusitis,
hypertension and cough. Twenty-two patients (5.2 %)
discontinued the study as a result of TEAEs. Changes in
IPSS, IPSS irritative and obstructive sub-scores, IPSS
health-related quality of life, BII, and IIEF–EF domain
in sexually-active patients with ED were maintained after
one year [77].
Regarding combination therapy of tadalafil and
α-blockers, two trials were analyzed. Bechara et al. [78]
randomized 30 men aged >50 years with LUTS/BPH into
two groups to receive once daily tamsulosin vs.
tamsulosin plus tadalafil 20 mg for 45 days and then
switched to the other treatment mode for another 45 days.
IIEF-EF significantly improved with tamsulosin plus
tadalafil (p<0.001) but not with tamsulosin alone. Im-
provements of IPSS were statistically significant with both
treatments but greater with combination therapy. Both
regimens similarly improved Qmax (p<0.001) with no
significant differences between tamsulosin monotherapy
vs. combination treatment (p>0.05). In the other study,
Liguori et al. [79] randomized 66 men with LUTS/BPH
and co-morbid ED and allocated these patients into three
treatment arms: alfuzosin 10 mg once daily (22 men),
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tadalafil 20 mg every second day (21 men), or a combi-
nation of both drugs (23 men). ED, as measured by the
IIEF-EF domain score, improved with alfuzosin alone
(+15 %) but much more with tadalafil alone (+36.3 %)
or combination therapy (+37.6 %). LUTS/BPH, as mea-
sured by IPSS, significantly improved with alfuzosin
(27.2 %) and combination therapy (41.6 %), but not with
tadalafil alone (8.4 %). Increase in Qmax was more pro-
nounced with combination therapy (29.6 %) than with
alfuzosin (21.7 %) or tadalafil monotherapy (9.5 %).
Overall [3••], TEAEs in men treated with tadalafil vs.
placebo were documented in 12.6 % (171/1360) vs. 5.3 %
(30/568) of patients while TEAEs in patients treated with
tadalafil vs. tadalafil plus α-blockers were 7.7 % (1/13) vs.
7.2 % (1/14).
Vardenafil
Stief et al. [80] published the first randomized, double-
blind, placebo-controlled study with vardenafil. In this
8-week multicenter trial, the authors included 221 men
who were equally distributed to vardenafil 10 mg
(n=108) or placebo (n=113) twice daily. Sexual func-
tion was significantly improved by vardenafil as com-
pared to placebo (IIEF-EF +7.5 vs. +1.5; p=0.0001). At
the same time, there was a significant improvement of
LUTS/BPH with vardenafil vs. placebo (IPSS −5.9 vs.
-3.6; p=0.0013). Although Qmax was more improved
with vardenafil, the difference compared to placebo
was not statistically significant (+1.6 ml/s vs. +1.0 ml/s;
p=0.5614).
Table 2 Characteristics of the studies included in the present analysis.
Weighted differences (with 95 % confidence interval [CI]) of Interna-
tional Prostate Symptom Score (IPSS), and International Index of
Erectile Function (IIEF) score for the studies on phosphodiesterase
type 5 inhibitors (PDE5-Is) versus placebo; PDE5-Is plus α-blocker
versus α-blocker alone (*)






















McVary KT, J Urol.
2007 [67]
4 60 14.6 - 7.6 6.2 9.0 −3.9 −5.4 −2.4
*Kaplan SA, Eur
Urol 2007 [71]
3 63.4 14.3 15.9 5.4 2.3 8.5 −1.1 −3.5 1.3
*Tuncel A, Word J
Urol 2010 [72]
2 58.8 - 15.4 - - - 0 −1.8 1.8
Tadalafil
McVary KT, J Urol
2007 [67]
3 61.5 14 17.9 6.8 4.3 9.3 −2.5 −3.9 −1.1
Roehrborn CG,
J Urol 2008 [73]
3 62.0 - 17 7.9 - −2.2 (20 mg) −4.6 0.2
Porst H, Eur Urol
2009 [74]
3 61.9 16 (20 mg arm) 16.1 5.2 (20 mg) 2.9 7.5 −4.7 - -
Porst H, Eur Urol
2011 [75]
3 64.8 - 16.8 4.7 2.5 6.9 −1.4 −3.9 1.1
*Bechara A, J Sex
Med 2008 [78]
3 63.7 15 19.4 6.3 0.9 11.7 −2.5 −5.7 0.7
*Liguori G, J Sex
Med 2009 [79]
3 6.,3 14.4 15 3.9 1.1 6.6 −1.5 −3.7 0.7
Oelke M, Eur Urol
2012 [76]
3 63.6 - 17.3 4.0 - - −2.1 - -
DonatucciF, BJU
Int. 2011 [77]
3 60.7 - - 5.9 Week 0
to endpoint




Stief CG, Eur Urol
2008 [80]
3 55.9 - 15.9 6.0 3.5 8.5 −2.2 −5.2 0.8
*Gacci M, J Sex
Med 2012 [81]
3 68.0 16.3 19.6 3.5 2.9 4.0 −3.8 −4.3 −3.3
The Jadad score assesses the quality of published clinical trials based methods relevant to random assignment, double blinding, and the flow of patients.
There are seven items in total; the last two attract a negative score, which means that the range of possible scores is 0 (bad) to 5 (good). LL= lower limit;
UL = upper limit
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Gacci et al. [81] compared the safety and efficacy of
once-daily tamsulosin plus placebo vs. tamsulosin plus
vardenafil 10 mg in 60 patients with LUTS/BPH in a ran-
domized, double blind trial with a 12-week follow-up. Erec-
tile function and LUTS were significantly improved with
combination therapy as compared to tamsulosin alone (IIEF-
EF combination +2.61 vs. tamsulosin alone +0.06, p=0.030;
IPSS combination −3.11 vs. -1.67, p=0.039). Furthermore,
vardenafil plus tamsulosin achieved an additional improve-
ment of Qmax compared to tamsulosin alone (+2.56 vs. +
0.07, p=0.034) Table 2.
Regarding the tolerability of vardenafil, the authors of a
systematic review found TEAEs in 38 % (40/105 men) vs.
3.6 % (4/110 men) in participants treated with vardenafil or
placebo while there were TEAEs in 10 % (3/30 men) with
vardenafil monotherapy compared to 6.9 % (2/29 men) with
vardenafil and α-blocker combination therapy [3••].
Conclusions
Epidemiological data underlines the strong association be-
tween ED and LUTS, either in the general population or in
urological patients. Moreover, ED and LUTS share several
common pathways which can be a potential target for
PDE5-Is, including NO/cGMP and RhoA/Rho-kinase path-
ways such as pelvic atherosclerosis and autonomic
hyperactivity.
PDE5-Is are well tolerated and effective for the treatment
of both ED and LUTS/BPH. Flushing, gastro-esophageal
reflux, headache and dyspepsia are the most frequently
reported adverse events. PDE5-Is significantly improve
erectile function, as measured with the IIEF-questionnaire,
and LUTS/BPH, as measured with the IPSS questionnaire,
with an overall improvement of quality of life.
PDE5-Is can be considered as the first choice of treatment
in men with both ED and LUTS/BPH but treatment of either
ED or LUTS/BPH with PDE5-Is is also feasible. Neverthe-
less, further studies are needed to evaluate the long-term
safety, efficacy, influence on disease progression, and cost-
effectiveness of PDE5-Is.
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